Not Yet Recruiting PHASE3 INTERVENTIONAL 2-arm
NCT06858722
Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (RIPERT-CIDP)
Safety and Efficacy of Ripertamab in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (RIPERT-CIDP): a Randomised, Double-blind, Multicentre, Placebo-controlled Phase 3 Trial
Sponsor: Zhongming Qiu
Interventions
Placebo ripertamab
Updated 1 time since 2025 Last updated: Feb 27, 2025 Started: Mar 15, 2025 Primary completion: Jun 30, 2027 Completion: Dec 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06858722, this PHASE3 trial focuses on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and remains actively recruiting participants. Sponsored by Zhongming Qiu, it has been updated 1 time since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE3
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Zhongming Qiu
Data source: Xinqiao Hospital of Chongqing
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.